购物车

全部删除
您的购物车当前为空

前往下单页继续购物

IL-23 Protein, Human, Recombinant (His & Avi), Biotinylated V2

一键复制产品信息

产品编号 TMPY-05648U

IL-23 Protein, Human, Recombinant (His & Avi), Biotinylated V2 is expressed in HEK293 Cells. The accession number is Q9NPF7(IL-23 alpha)&P29460(IL-12 beta).

IL-23 Protein, Human, Recombinant (His & Avi), Biotinylated V2

一键复制产品信息

产品编号 TMPY-05648U

IL-23 Protein, Human, Recombinant (His & Avi), Biotinylated V2 is expressed in HEK293 Cells. The accession number is Q9NPF7(IL-23 alpha)&P29460(IL-12 beta).

规格	价格	库存	数量

大包装 & 定制

TargetMol 的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

实验操作小课堂

常见问题解答

资源下载

重组蛋白用户指南

产品信息

生物活性	Immobilized Human IL-23R, His Tag at 5 μg/ml (100 μl/well) on the plate. Dose response curve for Biotinylated Human IL-23 alpha&IL-12 beta, His Tag with the EC50 of 0.87 μg/ml determined by ELISA.
产品描述	IL-23 Protein, Human, Recombinant (His & Avi), Biotinylated V2 is expressed in HEK293 Cells. The accession number is Q9NPF7(IL-23 alpha)&P29460(IL-12 beta).
种属	Human
表达系统	HEK293 Cells
标签	C-His-Avi
蛋白编号	Q9NPF7(IL-23 alpha)&P29460(IL-12 beta)
别名	白介素,SGRF,P19,IL23P19,IL-23A,IL-23,IL23
蛋白构建	Arg20-Pro189(IL-23 alpha) & Ile23-Ser328(IL-12 beta)
蛋白纯度	> 95% as determined by Tris-Bis PAGE
分子量	21.7 (IL-23 alpha) & 34.7 (IL-12 beta) kDa (Predicted); 24 kDa (IL-23 alpha) and 40-50 kDa (IL-12 beta) kDa (Due to glycosylation)
内毒素	< 1.0 EU/μg of the protein as determined by the LAL method.
蛋白性状	Lyophilized powder
缓冲液	Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
存储	Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
运输方式	In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice.
研究背景	The interleukin (IL)-12 family of cytokines, including IL12 and IL 23, play an important role in driving aberrant Th1 and Th17 immune responses in patients with Crohn's disease (CD). Targeting this pathway has opened new avenues for therapeutic intervention. The balance of proinflammatory cytokines interleukin (IL)-12 and IL-23 plays a key role in shaping the development of antitumor or protumor immunity.